You are here: Industry Insights > Heart failure

News List

FDA Approves New Treatment for Heart Failure with Reduced Ejection Fraction americanpharmaceuticalreview
May 08, 2020
The U.S. Food and Drug Administration (FDA) approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.
FDA approves Farxiga for heart failure expresspharma
May 06, 2020
Farxiga was shown in a clinical trial to improve survival and reduce the need for hospitalisation in adults with heart failure with reduced ejection fraction.
Novartis digital initiatives to create awareness of heart failure can positively impact patients’ lives in India: GlobalData expresspharma
April 15, 2020
According to GlobalData’s Pharma Intelligence Center, the diagnosed prevalence of congestive heart failure in India is currently around 9.61 million with an annual growth of 4 per cent.
Forxiga successful in DAPA-HF heart failure trial pharmatimes
March 31, 2020
New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo.
NHS data shows gap in care for heart failure patients pharmatimes
March 26, 2020
A new study published in a BMJ journal has found that inadequate screening in heart failure has cost the NHS an avoidable £21.5 million.
Fast Track Designation granted to decompensated heart failure treatment europeanpharmaceuticalreview
January 19, 2020
The US FDA has granted Fast Track Designation to APD418, which is in development as treatment for decompensated heart failure patients.
FDA Grants Fast Track Designation for Heart Failure Treatment americanpharmaceuticalreview
January 17, 2020
Arena Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
Outcomes Superior for HM3 LVAD Regardless of Preimplant Strategy drugs
January 16, 2020
For patients with advanced heart failure, the HeartMate 3 (HM3) left ventricular assist device (LVAD) is superior to the HeartMate II (HMII), regardless of whether the device is a bridge to transplant (BTT) or a destination therapy (DT) ...
Major Cardiovascular Diseases May Up Long-Term Risk for ESKD drugs
January 15, 2020
Major incident cardiovascular disease events are associated with an increased risk for end-stage kidney disease (ESKD), with the highest risk for heart failure, according to a study published online January in the Journal of the American Society of Nephro
AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF pharmaceutical-business-review
January 09, 2020
AstraZeneca’s Farxiga (dapagliflozin) has been granted priority review from the US Food and Drug Administration (FDA) for a certain population of patients with heart failure.

Previous page 1 2 3 4 5 6 7 Next page